Acclaro Medical continued to spotlight its 2,910 nm fiber laser technology this week through a mix of education-focused events and an expanded conference schedule. The company is emphasizing its UltraClear and AuraLux platforms as core to the future of aesthetic medicine and skin rejuvenation.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
At its Acclaro EDGE Scottsdale event, the company delivered high-engagement education, real-world clinical insights, and hands-on demonstrations of UltraClear and AuraLux. Sessions led by internal clinical leaders and outside experts focused on treatment strategies intended to deepen practitioner adoption and procedure utilization.
Acclaro is also promoting upcoming EDGE events in Boston and additional training under the Acclaro Aesthetics Academy in Napa, California. These programs combine clinical topics such as periorbital rejuvenation, scar remodeling, and skin of color best practices with business content on return-on-investment and marketing.
On the product side, the company continues to highlight UltraClear Laser-Coring as a differentiated approach within skin rejuvenation. Educational content led by its Senior Director of Clinical Excellence is designed to explain what makes the technique unique and to position fiber laser as an important modality in aesthetic treatments.
The AuraLux cold fiber laser platform remains another focus, with messaging around CoolPulse technology, treatment of all skin types, and patient comfort and healing. Acclaro presents AuraLux as a bridge for practices moving from skincare or injectables into energy-based procedures, aiming to support practice growth and recurring patient visits.
Commercially, Acclaro is ramping up its presence at major conferences across Asia, Europe, and the U.S., including AMWC Asia in Taipei, ASLMS 2026 in Savannah, and multiple meetings in Berlin, London, Boston, Stockholm, Biarritz, Las Vegas, and Nashville. The company plans live “Fiber Focus” sessions and before-and-after showcases at ASLMS to target a broad range of aesthetic and dermatologic indications.
Taken together, the week’s updates point to a coordinated push around education, KOL engagement, and global visibility for UltraClear and AuraLux. If these initiatives translate into higher device placements and procedure volumes, Acclaro Medical could see a stronger installed base, deeper customer relationships, and improved competitive positioning in the aesthetic laser market.